EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study

Boyoung Park, Eunyoung Lee, Junghyun Yoon, YoungJu Park, Hyeon-Seok Eom

Cancer Research and Treatment · 2024

DOI: 10.4143/crt.2023.843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Boyoung Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine, Hanyang University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasms, Second Primary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Janssen Korea Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study investigated the incidence of secondary malignancy in multiple myeloma (MM) patients compared with that in the general population using a population-based database covering all residents in Korea.Materials and Methods Based on the national health insurance system in Korea, all people primarily diagnosed with MM between January 1, 2010 to December 31, 2018 were identified. A total of 9,985 MM patients aged ≥ 20 years in Korea were included.

Results

Among them, 237 (2.4%) developed secondary malignancies by 2018. The standardized incidence rates (SIRs) of all secondary malignancies in MM patients were 0.87 (95% confidence interval [CI], 0.76 to 0.98), with a higher incidence of hematologic malignancies than in the general population with an SIR of 3.80 (95% CI, 2.61 to 5.00). The incidence rates of both lymphoid malignancy (SIR, 3.56; 95% CI, 2.31 to 4.82) and myeloid malignancy (SIR, 3.78; 95% CI, 1.16 to 6.39) were higher in MM patients than in the general population. In contrast, a lower incidence of solid cancer was observed in MM patients than in the general population (SIR, 0.76, 95% CI, 0.65 to 0.86). There was no significant difference in survival in MM patients without secondary malignancies, with hematologic malignancy, and with solid cancer (p=0.413).

Conclusion

MM patients had a greater risk of secondary malignancies, especially hematologic malignancies, than the general population. Future studies with a focus on analyzing patients’ history, treatment details, and genetic information in various stages of MM patients are needed to better understand the mechanism behind this increased risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeoplasms, Second PrimaryHumansRepublic of KoreaMaleFemaleMiddle AgedAgedIncidenceAdultAged, 80 and overYoung Adult

Stichwörter der Autor:innen

Hematologic neoplasmsMultiple myelomaSecondary malignancySolid cancer

Autor:innen und Institutionen

  • Department of Preventive Medicine, Hanyang University College of Medicine, Seoul, Korea.
  • Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
  • Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea.
  • Medical Affairs, Janssen Korea, Seoul, Korea.

Förderung

  • Janssen Korea Ltd.

Zitieren

APA

Park, B., Lee, E., Yoon, J., Park, Y., & Eom, H. S. (2024). Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.843

Vancouver

Park B, Lee E, Yoon J, Park Y, Eom HS. Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.843

BibTeX
@article{Park2024,
  author = {Park, Boyoung and Lee, Eunyoung and Yoon, Junghyun and Park, YoungJu and Eom, Hyeon-Seok},
  title = {Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study},
  journal = {Cancer Research and Treatment},
  year = {2024},
  doi = {10.4143/crt.2023.843}
}
Kostenlos starten →